الفهرس 
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 100 |  |  |
| | | from | 100 | | |
Abstract
SUMMARY
P
soriasis is a common chronic inflammatory disease of the skin and joints affecting approximately 2–3% of the world’s population. Skin lesions are characterized by red, scaly and well demarcated plaques that are the result of increased keratinocyte proliferation, dermal angiogenesis and infiltration of T cells, dendritic cells and monocytes.
Although the pathogenesis of psoriasis is still not fully understood, various proinflammatory cytokines (e.g., TNF-α, IL-1, IL-6, IL-17, IL-22, IL-23), and a number of cytokine receptors have been implicated in its pathogenesis and currently some of these are now under investigation as therapeutic targets.
Interleukin 5 (IL5), also known as eosinophil differentiation factor (EDF), is a lineage-specific cytokine for eosinophilpoiesis and it regulates eosinophil growth and activation.
Only limited data are available regarding the role of IL-5 in the progression of disease in patients with psoriasis.
So, this study aimed to evaluate the serum levels of interleukin 5 in psoriasis vulgaris patients and to assess the correlation between these serum levels and the disease severity.
This prospective case-control study was conducted at tertiary care hospital at Dermatology, Venereology and Andrology Department at Faculty of Medicine, Beni-Suef University from November 2020 to April 2021 and performed on total 100 participants divided into two groups, healthy control group and psoriasis group, who had mild, moderate to severe plaque psoriasis according to the Psoriasis Area Severity Index (PASI) score.
The diagnosis was based on the history and physical examination, all cases were subjected to full history taking including family history, and complete cutaneous examination and grading system. They were graded according to the Psoriasis Area Severity Index (PASI) score, in addition, 5ml of blood drown for laboratory investigation of IL-5.
There was a significant elevation in the serum levels of IL-5 in psoriasis patients’ group (p<0.001), in compare to the control group.
Regarding severity and PASI score psoriasis grades, our results showed that Median IL-5 level increased gradually with increased psoriasis grades (median IL-5 in mild, moderate, sever was 18.7, 38.6, 92.4 respectively; p<0.001).
There was a significant elevation of IL-5 level in patients who reported Koebner’s phenomenon (p=0.012) in comparison to those who did not report.